Assessment of the Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers in Patients With Mild Cognitive Disorders.

Trial Profile

Assessment of the Comparative Effect of Donepezil 10mg/d and Placebo on Clinical and Radiological Markers in Patients With Mild Cognitive Disorders.

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Oct 2016

At a glance

  • Drugs Donepezil (Primary)
  • Indications Mild cognitive impairment
  • Focus Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 25 Oct 2016 Results of post-hoc analysis, published in the Journal of Clinical Psychiatry.
    • 11 Jul 2014 Status changed to completed as reported by ClinicalTrials.gov record.
    • 20 Jul 2011 Results will be presented at the Alzheimer's Association International Conference 2011 (AAIC 2011) according to an Eisai media release. Results were also summarised in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top